Charles River NGS Services are now underpinning one of the more closely watched cell therapy manufacturing programs in oncology. Charles River Laboratories International, Inc. (NYSE: CRL) announced on July 13, 2026, that it will provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services to Arovella Therapeutics Ltd (ASX: ALA), an Australian biotechnology company developing an invariant Natural Killer T (iNKT) cell therapy platform for cancer.
The collaboration is built around cell characterization work that directly supported Arovella’s Investigational New Drug (IND) application to the U.S. Food and Drug Administration. As part of that successful filing, the FDA approved the use of NGS for viral safety testing of two cell banks that produce reagents used in manufacturing ALA-101, Arovella’s lead cell therapy candidate.
Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing at Charles River, framed the deal as a direct extension of the company’s client strategy. “Providing Arovella with NGS services as they advance a transformative iNKT cell therapy platform for patients with lymphoma and leukemia closely aligns with our strategic goal to deliver enhanced client experiences,” Dolph said, adding that the FDA’s acceptance of NGS in Arovella’s IND reflects the growing regulatory confidence in modern, GMP-ready sequencing for cell and gene therapy development.
Beyond the IND-supporting work, Charles River will also perform viral safety release testing on clinical batches of ALA-101 itself. ALA-101 is a next-generation, off-the-shelf CAR-iNKT cell therapy designed to treat CD19-positive B-cell lymphomas and leukemias, positioning it within the broader wave of allogeneic, meaning donor-derived, rather than patient-derived, cell therapies moving through clinical development.
Charles River NGS Services Bring GMP-Grade Sequencing to Arovella’s ALA-101 Program
Dr. Nicole van der Weerden, CEO of Arovella Therapeutics, described the arrangement as central to the company’s manufacturing quality strategy. “We are thrilled to collaborate with Charles River Laboratories to strengthen the foundation of our clinical manufacturing program,” she said. “By integrating advanced next-generation sequencing for comprehensive cell bank characterization and using a suite of validated viral safety tests for the release of clinical batches, we are reinforcing our commitment to the highest standards of safety, quality, and regulatory rigor and ensuring patients receive therapies backed by the most robust and innovative analytical approaches available.”
NGS technology has become a pivotal tool in advanced therapeutics because of how it changes the speed and depth of genetic characterization. High-throughput, scalable sequencing allows testing labs to detect pathogens and confirm genetic identity with a level of resolution that older methods struggle to match, which is precisely why regulators are increasingly comfortable accepting NGS-based data inside IND packages like Arovella’s.
How Charles River’s NGS Services and Biologics Testing Portfolio Support Arovella Therapeutics
To expand its sequencing footprint further, Charles River recently acquired Pathoquest, a company specializing in NGS solutions for in vitro characterization and quality control testing of biopharmaceutical products. Charles River says the acquisition lets it deliver faster, more advanced sequencing-based testing across the development pipeline, capabilities that now extend directly into the Arovella collaboration.
That sequencing work sits inside a much larger testing infrastructure. Charles River’s biologics testing arm draws on decades of cell banking and cell line characterization expertise, supported by nine CGMP-compliant ISO cleanroom suites, six of them dedicated cleanroom suites, an 8-to-10-week turnaround from cell bank completion to release, and a track record of more than 2,000 cell and viral banks produced for client programs spanning research through commercial manufacturing.
Charles River’s Cell Banking and Viral Safety Testing Capabilities
For Arovella, that infrastructure translates into two concrete deliverables: NGS-based characterization of the cell banks feeding ALA-101 production, and a validated suite of viral safety release tests applied to each clinical batch before it can move forward in the manufacturing chain.
About Arovella Therapeutics and ALA-101
Arovella Therapeutics Ltd (ASX: ALA) is developing its iNKT cell therapy platform, licensed from Imperial College London, to treat both blood cancers and solid tumors. Its lead candidate, ALA-101, consists of CAR19-iNKT cells engineered to express a Chimeric Antigen Receptor targeting CD19, an antigen present on numerous cancer types. Because iNKT cells also carry an invariant T-cell receptor that recognizes glycolipid-bound CD1d, another antigen expressed on several cancer types, the platform is designed to attack tumor cells through two distinct mechanisms simultaneously. ALA-101’s IND has been accepted by the FDA, and it is being developed as an allogeneic therapy, meaning doses can be manufactured from a healthy donor and given to multiple patients rather than requiring patient-specific manufacturing. Arovella is also expanding into solid tumors through CLDN18.2-targeting technology licensed from Sparx Group and plans to incorporate its IL-12-TM technology into those solid tumor programs.
